Publications

Export 8174 results:
Sort by: Author Title [ Type  (Asc)] Year
Journal Article
Abdelaziz, W. S., M. E. Ahmed, S. Sayed, and L. Gaabour, "Atomic structure data for neon like-VXIV ", Journal of Computational and Theoretical Nanoscience, vol. 14, 2017.
, "An atomic Theory with no prime models", Australasian Journal of Logic , vol. 5, issue 1, pp. 85-88, 2007.
Gao, W., A. O. Elnabawy, Z. D. Hood, Y. Shi, X. Wang, L. T. Roling, X. Pan, M. Mavrikakis, Y. Xia, and M. Chi, "Atomistic insights into the nucleation and growth of platinum on palladium nanocrystals", Nature communications, vol. 12, issue 1: Nature Publishing Group, pp. 1-10, 2021. Abstract
n/a
El-Yamany, M. F., S. M. Farrag, M. A. Hamzawy, M. Asaad, and N. N. Nassar, "Atorvastatin in nano-particulate formulation abates muscle and liver affliction when coalesced with coenzyme Q10 and/or vitamin E in hyperlipidemic rats", Life Sciences, vol. 203, pp. 129-140, 2018.
Farrag, S. M., M. A. Hamzawy, M. F. El-Yamany, M. Asaad, and N. N. Nassar, "Atorvastatin in nano-particulate formulation abates muscle and liver affliction when coalesced with coenzyme Q10 and/or vitamin E in hyperlipidemic rats", Life Sciences, vol. 203, pp. 129-140, 2018. AbstractWebsite
n/a
Farrag, S. M., M. A. Hamzawy, M. F. El-Yamany, M. Asaad, and N. N. Nassar, "Atorvastatin in nano-particulate formulation abates muscle and liver affliction when coalesced with coenzyme Q10 and/or vitamin E in hyperlipidemic rats.", Life sciences, vol. 203, pp. 129-140, 2018. Abstract

AIMS: Statins are the most widely used to lower elevated low-density lipoprotein levels and preventing cardiovascular diseases in humans. However, about 20% of patients treated with this medication suffer from statin-related myalgia. To this end, this study investigated the potential effect of nano-particulate formulation in alleviating the muscles and liver damage either alone or when co-administered with nano coenzyme Q10 and nano vitamin E.

MATERIALS AND METHODS: Male Wistar rats were fed normal diet or high-fat diet for 12 weeks, following which rats were treated with either (i) atorvastatin (5 or 20 mg/kg/day, p.o.) or (ii) atorvastatin with CoQ10 (10 mg/kg/day, p.o.) (iii) and/or vitamin E (30 mg/kg/day, p.o.) in free particle or nanoparticle forms for another 4 weeks. In all rats, serum total cholesterol (CH), triglycerides (TGs), low (LDL) and high (HDL) density lipoproteins, alanine (ALT) and aspartate (AST) transaminases, alkaline phosphatase (ALP), creatine kinase (CK), albumin (ALB), as well as hepatic malondialdehyde (MDA) and antioxidants "reduced glutathione (GSH) and superoxide dismutase (SOD)" were measured. Additionally quadriceps muscles and liver tissues were used for histopathological examination.

KEY FINDINGS: The antihyperlipidemic effect of statins was not altered when formulated as nanoparticles; albeit the former showed a prominent reduction in the liver and muscle enzymes and histopathological alterations together with a marked decline in the oxidative stress as compared to the free particulate form. These results were augmented when atorvastatin was combined with CoQ10 and/or Vit.E.

SIGNIFICANCE: Nanoparticulate formulation alleviated the statins induced liver and muscle damage especially when combined with CoQ10 and/or Vit.E.

Elgendy, H. A., A. M. A. Makky, Y. E. Elakkad, H. H. Awad, M. E. A. Hassab, and N. F. Younes, "Atorvastatin loaded lecithin‑coated zein nanoparticles based thermogel for the intra‑articular management of osteoarthritis: in‑silico, in‑vitro, and in‑vivo studies", Journal of Pharmaceutical Investigation, 2024.
Taha, N. M., H. - A. S. A. Yousof, S. H. El-Sayed, undefined, and M. S. I. Negm, "Atorvastatin repurposing for the treatment of cryptosporidiosis in experimentally immunosuppressed mice", Experimental Parasitology , vol. 181 , pp. 57-69, 2017.
Taha, N. M., H. E. B. A. T. - A. L. L. A. H. S. A. YOUSOF, S. H. El-Sayed, A. I. Younis, and M. S. I. Negm, "Atorvastatin repurposing for the treatment of cryptosporidiosis in experimentally immunosuppressed mice", Experimental parasitology , vol. 181, pp. 57-69 , 2017.
Taha, N. M., H. - A. S. A. Yousof, S. H. El-Sayed, A. I. Younis, and M. S. I. Negm, "Atorvastatin repurposing for the treatment of cryptosporidiosis in experimentally immunosuppressed mice", Experimental parasitology, vol. 181: Academic Press, pp. 57–69, 2017. Abstract
n/a
El-Nabarawi, N., M. El-wakd, and M. Salem, "Atorvastatin, a double weapon in osteoporosis treatment: an experimental and clinical study.", Drug design, development and therapy, vol. 11, pp. 1383-1391, 2017. Abstract

OBJECTIVE: The aim of this study was to evaluate the effect of atorvastatin on the bone formation and resorption markers in ovariectomized rats (experimental study), and to study its effect on the bone mineral density (BMD) in postmenopausal osteoporotic women (clinical study).

MATERIALS AND METHODS: The study involved experimental and clinical aspects. In the experimental aspect, 42 female Wistar rats were divided into five groups: Group I (n=6; sham-operated), Group II (n=6; 1 mL of carboxymethyl cellulose [CMC] was administered orally), Group III (n=6; 20 mg/kg orally of atorvastatin was administered), Group IV (n=12; untreated ovariectomized [OVX] rats and served as a model of osteoporosis [OP]) and Group V (n=12; 20 mg/kg orally of atorvastatin was administered to ovariectomized rats). After 4 weeks, serum acid phosphatase, alkaline phosphatase, osteocalcin, total calcium and inorganic phosphorus were assessed. Then, 3 µm thickness lumbar and femur sections were examined using a light microscope to assess cortical thickness, trabecular area, numbers of osteoblasts and osteoclasts. In the clinical aspect, 85 post-menopausal osteoporotic females with recently detected hyperlipidemia participated in the study. Atorvastatin 40 mg/day, calcium carbonate 500 mg/day and vitamin D 800 international units were given to all patients for a period of 18 months. BMD was measured at the start and at the end of the study by dual-energy X-ray absorptiometry (DEXA).

RESULTS: In the experiment aspect, the biomarkers of bone remodeling were notably elevated in the OVX group. Administration of atorvastatin produced a significant decrease in the level of these bone metabolic markers. Atorvastatin significantly ameliorates osteoporotic changes induced by ovariectomy. In the clinical aspect, after 18 months the DEXA showed improvement in the T-score for the three measured zones; however, these changes were statistically significant only in the femoral neck area.

CONCLUSION: Atorvastatin was able to decrease the rate of bone metabolism and increase osteogenic activity. It has dual mode of action; both anabolic and antiresorptive effect on bone. This lipophilic statin member may act as a double weapon drug.

Elmowafy, M., H. M. Ibrahim, M. A. Ahmed, K. Shalaby, A. Salama, and H. Hefesha, "Atorvastatin-loaded nanostructured lipid carriers (NLCs): strategy to overcome oral delivery drawbacks", Drug Delivery, vol. 24, no. 1: Taylor & Francis, pp. 932-941, 2017. AbstractWebsite

AbstractAtorvastatin (AT) is a widely used lipid-regulating drug to reduce cholesterol and triglycerides. Its poor aqueous solubility and hepatic metabolism require development of drug delivery systems able to improve its solubility and bypass hepatic effect. For this purpose, atorvastatin nanostructured lipid carriers (AT-NLCs) were prepared and characterized. AT-NLCs were prepared by emulsification using high-speed homogenization followed by ultrasonication. The prepared NLCs showed particle size between 162.5 ± 12 and 865.55 ± 28 nm while zeta potential values varied between −34 ± 0.29 and −23 ± 0.36 mV. They also showed high encapsulation efficiency (>87%) and amorphous state of the drug in lipid matrix. Pharmacokinetic parameters of optimized formulation (NLC-1; composed of 2% Gelucire® 43/01, 8% Capryol® PGMC, 2% Pluronic®F68 and 0.5% lecithin) revealed 3.6- and 2.1-fold increase in bioavailability as compared to atorvastatin suspension and commercial product (Lipitor®), respectively. Administration of NLC-1 led to significant reduction (p < .05) in the rats’ serum levels of total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL) and significant increase in high-density lipoprotein (HDL). This improvement was confirmed histologically by minimizing the associated hepatic steatosis. These investigations demonstrated the superiority of NLCs for improvement of oral bioavailability and in vivo performance of AT.

, "Atorvastatin: In-Vivo Synergy with Metronidazole as Anti-Blastocystis Therapy", Korean Journal of Parasitology, vol. Vol. 56, No. 2: 105-112, April 2018, issue Vol. 56, No. 2, pp. 105-112, 2018.
Maha M. A. Basyoni1, Shawky A. Fouad2, Marwa F. Amer3, Ahmed Fathy Amer4, and D. I. Ismail5, "Atorvastatin: In-Vivo Synergy with Metronidazole as Anti-Blastocystis Therapy", Korean Journal of Parasitology, vol. Vol. 56, No. 2: 105-112, April 2018, issue Vol. 56, No. 2, pp. 105-112, 2018.
Maha M. A. Basyoni1, Shawky A. Fouad2, Marwa F. Amer3, Ahmed Fathy Amer4, and D. I. Ismail5, "Atorvastatin: In-Vivo Synergy with Metronidazole as Anti-Blastocystis Therapy", Korean Journal of Parasitology, vol. Vol. 56, No. 2: 105-112, April 2018, issue ISSN (Online) 1738-0006, pp. 105-112, 2018. 01_kjp_17-250.pdf
Eid, S. M., S. S. Soliman, M. R. Elghobashy, and O. M. Abdalla, "ATR-FTIR coupled with Chemometrics for quantification of vildagliptin and metformin in pharmaceutical combinations having diverged concentration ranges", Vibrational Spectroscopy , vol. 106, pp. 102995, 1-8, 2020.
Mona K Galal, A. M. Morgan, Marwa A Ibrahim, and A. M. Hussien, "Atrazine-induced cell-mediated immunotoxicity in rabbits and the ameliorating role of glycyrrhizic acid", Environmental Science and Pollution Research (2021) 28:32027–32034, vol. 28, pp. 32027–32034, 2021. galal2021_article_atrazine-inducedcell-mediated.pdf
Wazni, O. M., W. Saliba, T. S. Fahmy, and A. Natale, Atrial arrhythmias after surgical maze: findings during catheter ablation. , , 2006.
Salam, A. M., E. Ertekin, I. M. van Hagen, J. Al Suwaidi, T. P. E. Ruys, M. R. Johnson, L. Gumbiene, A. A. Frogoudaki, K. A. Sorour, L. Iserin, et al., "Atrial Fibrillation or Flutter During Pregnancy in Patients With Structural Heart Disease: Data From the ROPAC (Registry on Pregnancy and Cardiac Disease)", JACC: Clinical Electrophysiology, vol. 1, no. 4: Elsevier, pp. 284–292, 2015. Abstract
n/a
Badr, I., R. Kamel, O. AbdElAziz, GaserAbdelmohsen, M. A. Mousa, and S. A. L. A. Salam, "Atrial flutter with brief periods of junctional ectopic tachycardia", Image, vol. 6, pp. 7, Submitted. Abstract
n/a
Abdel-Hafez, M. A., H. A. Hosny, H. Mostafa, S. A. Marzouk, and M. F. Ahmed, "Atrial Natriuretic Peptide and Leptin in Obesity-associated Hypertension in Middle-aged Egyptian Women ", Bulletin of Egyptian Society for Physiological Sciences , vol. 31, issue 1, pp. 271-284, 2011. atrial_natriuretic_peptide.pdf
Abdel-Hafez, M. A., H. H. Ahmed, H. A. Mostafa, S. A. Marzouk, and M. F. Ahmed, "Atrial Natriuretic Peptide and Leptin in Obesity-associated Hypertension in Middle-aged Egyptian Women", Bull. Egypt. Soc. Physiol. Sci, vol. 31, issue 1, pp. 271-284, 2011.
Tourism